The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Novel trends in high-throughput screening
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391
Origin and evolution of high throughput screening
Pereira, D. A., & Williams, J. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707373 · Cited by 364
Screening in a spirit haunted world
Shoichet, B. K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.014 · Cited by 276
The Future of High-Throughput Screening
Mayr, L. M., & Fuerst, P. (2008) · SLAS Discovery · doi:10.1177/1087057108319644 · Cited by 276
Self-citationCritical review of the role of HTS in drug discovery
Macarron, R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.001 · Cited by 241
Inhibition of a viral enzyme by a small-molecule dimer disruptor
Shahian, T., Lee, G., Lazic, A., Arnold, L. A., Velusamy, P., Roels, C. M., Guy, R. K., & Craik, C. S. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.192 · Cited by 81
Screening of Small Molecule Interactor Library by Using In-Cell NMR Spectroscopy (SMILI-NMR)
Xie, J., Thapa, R., Reverdatto, S., Burz, D. S., & Shekhtman, A. G. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9000743 · Cited by 80
Evaluating Real-Life High-Throughput Screening Data
Gribbon, P. M., Lyons, R., Laflin, P., Bradley, J., Chambers, C., Williams, B. S., Keighley, W. W., & Sewing, A. (2005) · SLAS DISCOVERY · doi:10.1177/1087057104271957 · Cited by 71
Brandish, P. E., Chiu, C., Schneeweis, J. E., Brandon, N. J., Leech, C. L., Kornienko, O., Scolnick, E. M., Strulovici, B., & Zheng, W. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106288181 · Cited by 59
Case study: impact of technology investment on lead discovery at Bristol–Myers Squibb, 1998–2006
Houston, J. G., Banks, M. N., Binnie, A., Brenner, S. L., O’Connell, J., & Petrillo, E. W. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.004 · Cited by 49
Diversity-Oriented Organic Synthesis and Proteomics
Schreiber, S. L., Nicolaou, K. C., & Davies, K. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00088-1 · Cited by 45
Klumpp, M., Boettcher, A., Becker, D., Meder, G., Blank, J., Leder, L., Forstner, M., Ottl, J., & Mayr, L. M. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106288444 · Cited by 43
Self-citationHigh-Content Analysis in Preclinical Drug Discovery
Denner, P., Schmalowsky, J., & Prechtl, S. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708783877780 · Cited by 34
A Fluorescence Lifetime-Based Assay for Protease Inhibitor Profiling on Human Kallikrein 7
Doering, K., Meder, G., Hinnenberger, M., Woelcke, J., Mayr, L. M., & Hassiepen, U. (2009) · SLAS DISCOVERY · doi:10.1177/1087057108327328 · Cited by 30
Self-citationFragment-Based Drug Discovery Using Rational Design
Jhoti, H. (2007) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2007_064 · Cited by 22
Cited by
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
Thirumurugan, P., Matosiuk, D., & Jozwiak, K. (2013) · Chemical Reviews · doi:10.1021/cr200409f · Cited by 1,896
Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17
Ruddigkeit, L., van Deursen, R., Blum, L. C., & Reymond, J.-L. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300415d · Cited by 1,505
Target identification and mechanism of action in chemical biology and drug discovery
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1199 · Cited by 1,096
Rethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
Reymond, J.-L. (2015) · Accounts of Chemical Research · doi:10.1021/ar500432k · Cited by 720
Metadata
- Authors
- Mayr, L. M., & Bojanic, D.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 9
- Issue
- 5
- Pages
- 580-588
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2046588282
- Cited by
- 694
- References
- 21
- FWCI
- 38.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.